Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

Functional and Structural Outcomes Following Childhood Bone or Soft Tissue Sarcomas of the Lower ExtremityActive Not Recruiting
NCT06737172N/AUpdated Aug 18, 2026
Sponsor: Technical University of Munich
Soft Tissue Sarcoma of the Lower Extremity · Bone Sarcoma of the Lower Extremity · Childhood and Adolescent Cancer
Germany
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)Terminated
NCT05665595Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Argentina, Australia, Austria, Belgium +21 more
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruiting
NCT07201922Phase 3Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Familial Pulmonary Fibrosis · Interstitial Lung Abnormalities · Interstitial Lung Diseases
United States, Argentina, Australia, Belgium, Canada +8 more
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruiting
NCT07067463Phase 3Updated Aug 18, 2026
Sponsor: Zenas BioPharma (USA), LLC
Multiple Sclerosis (MS) Primary Progressive
United States, Bulgaria, Croatia, Czechia, Estonia +8 more
Continuous Finger-cuff Arterial Pressure Monitoring and Intraoperative Hypotension During Non-cardiac Surgery: the Randomized DETECT II TrialCompleted
NCT06753097NAUpdated Aug 18, 2026
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Intraoperative Hypotension
Germany
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary FibrosisRecruiting
NCT06855329N/AUpdated Aug 18, 2026
Sponsor: University of Massachusetts, Worcester
Progressive Pulmonary Fibrosis · Interstitial Lung Disease
United States, Australia, Austria, Canada, Czechia +8 more
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Recruiting
NCT06997588Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Australia, Austria, Belgium, France +5 more
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusActive Not Recruiting
NCT06559163Phase 2Updated Aug 18, 2026
Sponsor: Zenas BioPharma (USA), LLC
Systemic Lupus Erythematosus
United States, Belgium, Bulgaria, Canada, China +13 more
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active Not Recruiting
NCT05156281Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Brazil, Bulgaria, Canada +22 more
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)Completed
NCT04880434Phase 2Updated Aug 18, 2026
Sponsor: Kite, A Gilead Company
Relapsed/Refractory Mantle Cell Lymphoma
United States, France, Germany, Netherlands, Spain +1 more
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerRecruiting
NCT06764485Phase 3Updated Aug 18, 2026
Sponsor: Celgene
Metastatic Castration-resistant Prostate Cancer
United States, Argentina, Australia, Austria, Brazil +21 more
A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are ToleratedActive Not Recruiting
NCT07526194Phase 1Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Healthy
Germany
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Recruiting
NCT07291076Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Hepatocellular Carcinoma (HCC)
United States, Australia, Chile, China, France +9 more
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminated
NCT05853458Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Polycythemia Vera
Germany
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBMRecruiting
NCT05902169Phase 3Updated Aug 18, 2026
Sponsor: CarThera
Glioblastoma · Recurrent Glioblastoma · GBM
United States, Austria, Belgium, Denmark, France +6 more
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruiting
NCT04772079Phase 3Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Plaque Psoriasis
Argentina, Australia, Brazil, Canada, France +8 more
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Recruiting
NCT06615479Phase 3Updated Aug 18, 2026
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed or Refractory Multiple Myeloma (RRMM)
United States, Argentina, Australia, Austria, Belgium +26 more
A Study in Healthy People to Compare Two Tablet Formulations of PramipexoleRecruiting
NCT07727785Phase 1Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Healthy
Germany
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)Active Not Recruiting
NCT06625411Phase 3Updated Aug 18, 2026
Sponsor: Viridian Therapeutics, Inc.
Thyroid Eye Disease
United States, Germany, Hungary, Netherlands, Spain
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruiting
NCT07226986Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
United States, Australia, France, Germany, Italy +2 more
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNot Yet Recruiting
NCT07768813Phase 1Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Healthy · Obesity
Germany
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruiting
NCT06090539Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Bristol-Myers Squibb
Relapsed/Refractory Non-Hodgkin Lymphoma
United States, Chile, China, France, Germany +10 more
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompleted
NCT03106779Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
United States, Argentina, Australia, Brazil, Bulgaria +20 more
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Active Not Recruiting
NCT06625398Phase 3Updated Aug 18, 2026
Sponsor: Viridian Therapeutics, Inc.
Thyroid Eye Disease
United States, Germany, Hungary, Netherlands, Poland +1 more
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein ThrombosisRecruiting
NCT05701917NAUpdated Aug 18, 2026
Sponsor: Inari Medical
Venous Thromboembolism · Deep Venous Thrombosis · Post-Thrombotic Syndrome
United States, Austria, Finland, Germany, Switzerland +1 more

Previous page Next page